SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Greed Is Good who wrote (193)12/22/1997 5:11:00 AM
From: Harry D. Kramer  Read Replies (1) of 1510
 
Hi Greed,
I am a long-term investor in IMNR and I don't care too much about short-term movements, especially at the end of December. This time of the year has never been an easy call. I have no new information regarding IMNR that would change my view on the company's future. I agree with Mark that the last few days were normal profit taking, although I don't buy the reason. The fact that we won't hear any interim results from the Remune trial until late in the second quarter 1998 is not new. This has been in the market for quite some time. IMO, last weeks drop was also related to options expiration.

I agree with you that we can find many reasons to overweight the biotech sector right now (see my ATIS post #1226), but the market doesn't really care about it, as we have seen in the last few days. Uncertainty is high and will remain high for the next few weeks, and in such an environment Wall Street will stay away from the high-risk stuff. And biotech as a group is still sky-high risk!

Harry
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext